Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
- Associated Therapies
- -
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT02014636
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 353
- Registration Number
- NCT02009449
- Locations
- 🇺🇸
UCLA Medical Hematology & Oncology, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT01995981
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
🇬🇧Royal Marsden Hospital, London, United Kingdom
Combined Modality Treatment of Sarcomas of the Extremities
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01985295
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Noord Holland, Netherlands
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT01956669
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT01931098
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 120
- Registration Number
- NCT01861951
- Locations
- 🇩🇪
University Hospital RWTH Aachen, Medical Dept. IV, Aachen, North Rhine-Westphalia, Germany
🇩🇪University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany
🇩🇪University Medical Centre Mannheim, Surgical oncology, Mannheim, Baden-Wuerttemberg, Germany
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 30
- Registration Number
- NCT01832259
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Pazopanib Maintenance for SCLC
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 97
- Registration Number
- NCT01797874
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- George Clinical Pty Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT01759303
- Locations
- 🇺🇸
Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.